Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Outlines Agenda For Cybersecurity Workshop

This article was originally published in The Gray Sheet

Executive Summary

Topics that will be addressed at an upcoming FDA cybersecurity meeting include postmarket management, risk assessment, the challenges of collaboration and developing cybersecurity standards.

You may also be interested in...



FDA Says It Is Changing Its Cybersecurity Culture, And Others Should Too

Speaking at the 2015 mHealth Summit, Suzanne Schwartz, the FDA device center's top cybersecurity expert, said the agency is undergoing a cultural shift to better deal with device cybersecurity vulnerabilities and urged manufacturers, security researchers and hospitals to do the same.

FDA Cybersecurity Efforts Emphasize Collaboration With Homeland Security Officials, Hospitals

CDRH’s emergency preparedness director spelled out the device center’s cybersecurity efforts during a recent webinar. The efforts go beyond guidance and regulations and include proactive steps to tackle the challenge, including weekly meetings with the Department of Homeland Security, she said.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel